Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation

被引:56
作者
Hine, David [2 ]
Mackness, Bharti [1 ]
Mackness, Mike [1 ]
机构
[1] C LARGELAGAR, PONTECH ART, Cap Salou 43840, Salou, Spain
[2] Univ Manchester, Div Cardiovasc Res, Manchester M13 9WL, Lancs, England
关键词
paraoxonase-1; apo A1; LCAT; HDL; oxidation; LOW-DENSITY-LIPOPROTEIN; SERUM PARAOXONASE; CHOLESTEROL ACYLTRANSFERASE; LIPID HYDROPEROXIDES; PLASMA LECITHIN; GENE-TRANSFER; ATHEROSCLEROSIS; MICE; INHIBITION; ABILITY;
D O I
10.1002/iub.588
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The inhibition of low-density lipoprotein (LDL) oxidation by high-density lipoprotein (HDL) is a major antiatherogenic property of this lipoprotein. This activity is due, in part, to HDL associated proteins. However, whether these proteins interact in the antioxidant activity of HDL is unknown. LDL was incubated with apolipoprotein A1 (apo A1), lecithin:cholesterol acyltransferase (LCAT), and paraoxonase-1 (PON1) alone or in combination, in the presence or absence of HDL under oxidizing conditions. LDL lipid peroxide concentrations were determined. Apo A1, LCAT, and PON1 all inhibit LDL oxidation in the absence of HDL and enhance the ability of HDL to inhibit LDL oxidation. Their effect was additive rather than synergistic; the combination of these proteins significantly enhanced the length of time LDL was protected from oxidation. This seemed to be due to the ability of PON1 to prevent the oxidative inactivation of LCAT. Apo A1, LCAT, and PON1 can all contribute to the antioxidant activity of HDL in vitro. The combination of apo A1, LCAT, and PON1 prolongs the time that HDL can prevent LDL oxidation, due, at least in part, to the prevention LCAT inactivation. (c) 2011 IUBMB Life,, 2011.
引用
收藏
页码:157 / 161
页数:5
相关论文
共 21 条
[1]
Arrol S., 1996, European Journal of Laboratory Medicine, V4, P33
[2]
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants [J].
Aviram, M ;
Rosenblat, M ;
Billecke, S ;
Erogul, J ;
Sorenson, R ;
Bisgaier, CL ;
Newton, RS ;
La Du, B .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (7-8) :892-904
[3]
Bielicki JK, 1999, J LIPID RES, V40, P948
[4]
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits [J].
Duverger, N ;
Kruth, H ;
Emmanuel, F ;
Caillaud, JM ;
Viglietta, C ;
Castro, G ;
Tailleux, A ;
Fievet, C ;
Fruchart, JC ;
Houdebine, LM ;
Denefle, P .
CIRCULATION, 1996, 94 (04) :713-717
[5]
GAN KN, 1991, DRUG METAB DISPOS, V19, P100
[6]
Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress [J].
Liu, Yifen ;
Mackness, Bharti ;
Mackness, Mike .
FREE RADICAL BIOLOGY AND MEDICINE, 2008, 45 (06) :743-748
[7]
Atherosclerosis [J].
Lusis, AJ .
NATURE, 2000, 407 (6801) :233-241
[8]
Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome [J].
Mackness, Bharti ;
Quarck, Rozenn ;
Verreth, Wim ;
Mackness, Mike ;
Holvoet, Paul .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (07) :1545-1550
[9]
High-density lipoprotein: why all the fuss? [J].
Mackness, Bharti ;
Mackness, Mike .
ANNALS OF CLINICAL BIOCHEMISTRY, 2009, 46 :5-7
[10]
THE ROLE OF HIGH-DENSITY-LIPOPROTEIN AND LIPID-SOLUBLE ANTIOXIDANT VITAMINS IN INHIBITING LOW-DENSITY-LIPOPROTEIN OXIDATION [J].
MACKNESS, MI ;
ABBOTT, C ;
ARROL, S ;
DURRINGTON, PN .
BIOCHEMICAL JOURNAL, 1993, 294 :829-834